High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma
High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma
复制标题
DOI：
10.1002/jmv.24423
复制
发表时间：
2016-06-01
影响因子：
12.7
通讯作者：
Yoon, Jung-Hwan
中科院分区：
文献类型：
--
作者：
Cho, Yuri;Yu, Su Jong;Yoon, Jung-Hwan
利妥昔单抗是一种抗 CD20 单克隆抗体，与乙型肝炎病毒 (HBV) 重新激活的风险增加有关。本研究旨在确定已治愈乙型肝炎患者（定义为 HBsAg 阴性、抗 HBc 阳性和 HBV DNA 检测不到）中与利妥昔单抗相关的 HBV 再激活的预测因素。 2003 年至 2014 年，在首尔国立大学医院连续接受了以利妥昔单抗为基础的化疗的 840 名 CD20 阳性 B 细胞淋巴瘤患者中，有 732 名患者因未评估抗 HBc 或 HBsAg 血清阳性而被排除。这项回顾性研究包括 108 名已治愈的乙型肝炎患者。在中位 33.5 个月的随访期内，仅在抗 HBs 滴度较低的患者中发生了 8 例 HBV 再激活（
Rituximab, an anti-CD20 monoclonal antibody, is associated with an increased risk of hepatitis B virus (HBV) reactivation. This study aimed to determine the predictive factors for rituximab-related HBV reactivation in resolved hepatitis B patients, defined as HBsAg-negative, anti-HBc-positive, and undetectable HBV DNA. Among 840 consecutive patients with CD20-positive B-cell lymphoma who received rituximab-based chemotherapy from 2003 through 2014 at Seoul National University Hospital, 732 patients were excluded because either anti-HBc was not assessed or they were HBsAg-seropositive. This retrospective study included 108 resolved hepatitis B patients. During a median 33.5-month follow-up period, eight cases of HBV reactivation occurred only among the patients with low anti-HBs titers (